What one share of Tarsus Pharmaceuticals holds
We are a commercial stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. We launched XDEMVY® (lotilaner ophthalmic solution) 0.25%, formerly known as TP-03, for the treatment of Demodex blepharitis, in August 2023 after receiving U.S.
Tarsus Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $14.12 |
|---|---|
| Profit | −$1.08 |
| Capex (buildings and equipment) | $0.42 |
| Free cash flow | $1.30 |
| Cash and investments | $10.39 |
| Debt | $1.68 |
| Book value | $8.01 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2019 | — | −$1.98 | $0.07 | −$1.63 | $0.00 | −$2.27 |
| 2020 | $0.00 | −$4.32 | $0.07 | −$3.48 | $0.00 | — |
| 2021 | $2.77 | −$0.67 | $0.03 | $0.15 | $0.00 | $8.06 |
| 2022 | $1.05 | −$2.52 | $0.02 | −$2.01 | $0.00 | $7.22 |
| 2023 | $0.59 | −$4.62 | $0.05 | −$4.05 | $0.00 | $5.76 |
| 2024 | $4.87 | −$3.07 | $0.04 | −$2.25 | $0.00 | $5.85 |
| 2025 | $10.80 | −$1.59 | $0.24 | −$0.53 | $0.00 | $8.07 |
Common questions about Tarsus Pharmaceuticals
How much does one share of Tarsus Pharmaceuticals earn?
Over the last 12 months, Tarsus Pharmaceuticals lost $1.08 for each share on $14.12 of sales.
Does Tarsus Pharmaceuticals pay a dividend?
Tarsus Pharmaceuticals didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Tarsus Pharmaceuticals’s book value per share?
Tarsus Pharmaceuticals’s book value is $8.01 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Tarsus Pharmaceuticals have?
Each share of Tarsus Pharmaceuticals has $10.39 of cash and investments and $1.68 of debt, as of June 30, 2026.
What is Tarsus Pharmaceuticals’s free cash flow per share?
$1.30 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Tarsus Pharmaceuticals bought back shares?
Tarsus Pharmaceuticals’s share count rose about 1668% from 2019 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.